Fierce Biotech

uniQure's ballyhooed gene therapy for Huntington's hits FDA roadblock

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...
Fierce Biotech

Tempero calls time on alcohol use disorder while mulling options, according to partner

Tempero Bio has hit the brakes on a phase 2-stage alcohol use disorder (AUD) candidate while the biotech considers its ...
Fierce Biotech

Roche signs $2B pact to pilot Manifold Bio's shuttles to the brain

Roche may have been exploring ways to shuttle drugs to the brain for well over a decade, but that’s not stopping the pharma from ...
Fierce Biotech

TScan lays off 30% of workforce, halts phase 1 solid tumor T-cell receptor trial

TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid ...
Fierce Biotech

Neurocrine pens $880M deal with China's TransThera for red-hot immunology target

Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in ...
Fierce Biotech

Pfizer sues Metsera over Novo's shock counteroffer, but obesity biotech stands firm

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales ...
Fierce Biotech

Italian biotech AAVantgarde adds $143M series B to fund retinal disease gene therapy trials

Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series ...